On December 15, 2020, Radius announced a discovery research collaboration with Massachusetts General Hospital (MGH) to evaluate novel oral salt-inducible kinase (SIK) inhibitors in an array of ...

Radius Health, which is testing injectable and microneedle patch versions of its lead osteoporosis drug, filed plans Feb. 6 to dive into the public markets. The IPO is ambitious for life sciences ...

Investors plowed another big chunk of capital into startup Radius Health as the company funds an ongoing pivotal study for its bone-building drug for osteoporosis, a bone-thinning ailment that effects ...

Radius Health Inc (NASDAQ: RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and ...

When Radius Health scored an early approval for its osteoporosis med Tymlos last month, industry watchers thought it wouldn't be long before the drug had to contend with another newcomer from Amgen.